^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Vitrakvi (larotrectinib)

    i
    Other names: LOXO-101, ARRY 470, ARRY-470, LOXO 101, LOXO101, ARRY470, BAY2757556, BAY 2757556, BAY-2757556
    Company:
    Bayer, Pfizer
    Drug class:
    TrkA receptor inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor
    Related drugs:
    Apply
    A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children (SCOUT) (NCT02637687)
    Phase 1/2
    Bayer
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    12/16/2015
    Primary completion :
    07/20/2024
    Completion :
    09/30/2026
    NTRK3 • ETV6 • NTRK
    |
    NTRK positive • NTRK fusion
    |
    carboplatin • Vitrakvi (larotrectinib) • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
    A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma with NTRK Fusion (CONNECT1903) (NCT04655404)
    Phase 1
    Nationwide Children's Hospital
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    04/08/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    NTRK
    |
    NTRK fusion
    |
    Vitrakvi (larotrectinib)
    Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body (ON-TRK) (NCT04142437)
    Phase N/A
    Bayer
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    04/03/2020
    Primary completion :
    11/30/2029
    Completion :
    03/31/2030
    NTRK1 • NTRK3 • NTRK2 • NTRK
    |
    NTRK fusion
    |
    Vitrakvi (larotrectinib)
    A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) (NCT02576431)
    Phase 2
    Bayer
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    09/30/2015
    Primary completion :
    07/20/2025
    Completion :
    10/31/2025
    NTRK1 • NTRK3 • NTRK2
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion
    |
    Vitrakvi (larotrectinib)
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • cisplatin • Mekinist (trametinib) • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • capecitabine • Talzenna (talazoparib) • Piqray (alpelisib) • enzalutamide • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • eribulin mesylate • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • methotrexate • Truqap (capivasertib) • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • carmustine • Erivedge (vismodegib) • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • melphalan • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • fludarabine IV • Zynyz (retifanlimab-dlwr) • avadomide (CC-122) • Ostarine (enobosarm) • vistusertib (AZD2014) • mesna • Myocet (non-pegylated liposomal doxorubicin) • vinblastine • lorvotuzumab mertansine (IMGN901) • Xofigo (radium Ra-223 dichloride) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ieramilimab (LAG525) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • levoleucovorin calcium • methotrexate IV • Pertuvia (pertuzumab biosimilar) • sapitinib (AZD8931) • Vasforda (bevacizumab biosimilar)
    Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (NCT03155620)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    07/31/2017
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    BRAF
    |
    Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)
    Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) (NCT03213704)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    08/23/2017
    Primary completion :
    09/30/2024
    Completion :
    10/08/2025
    NTRK
    |
    NTRK fusion
    |
    Vitrakvi (larotrectinib)
    TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (NCT02693535)
    Phase 2
    American Society of Clinical Oncology
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    03/14/2016
    Primary completion :
    06/30/2026
    Completion :
    06/30/2027
    BRAF
    |
    ER positive • HER-2 negative • PGR positive
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • temsirolimus • letrozole • axitinib • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension
    A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database (NCT05236257)
    Phase N/A
    Bayer
    Completed
    Last update posted :
    12/10/2024
    Initiation :
    03/10/2022
    Primary completion :
    09/13/2022
    Completion :
    09/13/2022
    NTRK
    |
    NTRK fusion
    |
    Vitrakvi (larotrectinib)
    Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer (NCT05783323)
    Phase 2
    Children's Hospital of Philadelphia
    Recruiting
    Last update posted :
    11/12/2024
    Initiation :
    02/14/2024
    Primary completion :
    10/01/2026
    Completion :
    10/01/2027
    NTRK1 • NTRK3 • NTRK2 • NTRK
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion
    |
    Vitrakvi (larotrectinib)
    Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors (NCT04879121)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    05/07/2024
    Initiation :
    04/30/2021
    Primary completion :
    11/11/2025
    Completion :
    11/11/2025
    NTRK1 • NTRK3 • NTRK2
    |
    Vitrakvi (larotrectinib)
    Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia (ADVL1823) (NCT03834961)
    Phase 2
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    03/22/2024
    Initiation :
    10/25/2019
    Primary completion :
    09/30/2024
    Completion :
    09/30/2024
    NTRK1 • NTRK3 • NTRK2 • ETV6
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion
    |
    Vitrakvi (larotrectinib)